BCGitis or genitourinary tuberculosis? Diagnostic dilemma following intravesical Bacillus Calmette-Guérin therapy: a case report.

Publication date: Jul 01, 2026

Intravesical Bacillus Calmette-GucE9rin (iBCG) therapy is a cornerstone in the management of non-muscle-invasive bladder cancer. Although generally safe, it can rarely lead to granulomatous inflammatory complications that closely mimic recurrent malignancy or genitourinary tuberculosis, particularly in tuberculosis-endemic regions. A 47-year-old male with type 2 diabetes mellitus and high-grade T1 non-muscle-invasive bladder carcinoma underwent transurethral resection followed by iBCG induction and maintenance therapy. One month after completing the third maintenance cycle, he developed hematuria and persistent lower urinary tract symptoms. Urinalysis revealed sterile pyuria and hematuria, and imaging demonstrated a new focal bladder wall lesion. Cystoscopic biopsy showed granulomatous inflammation with caseous necrosis without malignancy. Urine was positive for acid-fast bacilli and Mycobacterium tuberculosis complex on GeneXpert. Considering the recent iBCG therapy, a diagnosis of BCG-associated granulomatous cystitis (BCGitis) was made. BCG therapy was stopped, and anti-tubercular therapy with isoniazid, rifampicin, and ethambutol was initiated. BCG-induced granulomatous cystitis represents a diagnostic challenge due to its clinical, radiological, and cystoscopic resemblance to bladder cancer recurrence and genitourinary tuberculosis. In tuberculosis-endemic settings, differentiating these entities is particularly difficult. Histopathology remains central to diagnosis, while molecular techniques may aid in species differentiation when available. Awareness of this complication allows timely diagnosis and avoids unnecessary invasive interventions or overtreatment. BCGitis is a rare but important complication of iBCG therapy. A high index of suspicion, combined with careful clinicopathological correlation, is essential for accurate diagnosis and appropriate management, especially in tuberculosis-endemic regions.

Concepts Keywords
Cancer BCGitis
Diabetes genitourinary tuberculosis
Month intravesical BCG
Safe
Urinalysis

Semantics

Type Source Name
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease MESH non-muscle-invasive bladder cancer
disease MESH malignancy
disease MESH type 2 diabetes mellitus
disease MESH hematuria
disease MESH lower urinary tract symptoms
disease MESH inflammation
disease MESH necrosis
drug DRUGBANK BCG vaccine
disease MESH cystitis
drug DRUGBANK Isoniazid
drug DRUGBANK Rifampicin
drug DRUGBANK Ethambutol
disease MESH bladder cancer
pathway KEGG Bladder cancer
disease MESH recurrence

Original Article

(Visited 15 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *